Dr Reddy's Q2 Preview: Healthy double-digit revenue growth seen, but PAT may fall
Dr. Reddy's Laboratories is likely to report healthy double-digit growth in sales in the second quarter, mainly driven by strong domestic and US businesses. However, the bottom line is seen declining in the reporting period.
Net profit for the July-September 2024 period may fall 3% year-on-year, according to an average estimate of four brokerages. Meanwhile, sales are likely to grow 13% year-on-year, the estimates revealed.
Analysts are building US revenue at $419 million, driven by strong gRevlimid contribution. The India business may rise 19% YoY driven by organic 11% YoY growth and Rs 100 crore contribution of the vaccine business.
Here's what to expect from Dr Reddy's Q2:
Kotak Equities
We expect the North American base business (ex-gRevlimid) sales to decline 2% QoQ to $330 million driven by flat volumes across most molecules. In our estimates, we factor in $130 million of gRevlimid sales in the US in 2QFY25 for DRRD, higher than $125 million in 1QFY25.
Stock Trading
ROC Made Easy: Master Course for ROC Stock Indicator
By — Souradeep Dey, Equity and Commodity Trader, Trainer
Stock Trading
Algo Trading Made Easy
By — Vivek Gadodia, Partner at Dravyaniti Consulting and RBT Algo Systems
Stock Trading
Heikin Ashi Trading Tactics: Master the Art of Trading
By — Dinesh Nagpal, Full Time Trader, Ichimoku & Trading Psychology Expert
Stock Trading
Technical Trading Made Easy: Online Certification Course
By — Souradeep Dey, Equity and Commodity Trader, Trainer
Stock Trading
Introduction to Technical Analysis & Candlestick
